SPARC/Sec/SE/2023-24/63 October 30, 2023

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Scrip Symbol: SPARC

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 532872

Dear Sir/Madam,

Sub: Press Release: SPARC Completes Enrolment in PROSEEK, A Global Phase 2 Study of Vodobatinib in Early Parkinson's Disease

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release on the above mentioned subject, which we shall be releasing after sending this letter to you.

This is for your information and dissemination.

Yours faithfully,

For **Sun Pharma Advanced Research Company Ltd.**

KAJAL DAMANIA

Digitally signed by KAJAL DAMANIA
DN: cn=KAJAL DAMANIA, o=SPIL.COM, ou=SPIL, email=kajal.damania@sparcmail.com, c=IN
Date: 2023.10.30 08:57:36 +05'30'

Kajal Damania
Company Secretary and Compliance Officer
ICSI Membership No. A29764

Encl: As above

FOR IMMEDIATE RELEASE

SPARC Completes Enrolment in PROSEEK, A Global Phase 2 Study of Vodobatinib in Early Parkinson's Disease

- *506 patients completed enrolment across 84 sites in the US, Europe & India*
- *PROSEEK is one of the largest Phase 2 study in patients with early Parkinson's disease*

MUMBAI, India October 30, 2023, Sun Pharma Advanced Research Company Ltd. (SPARC)(Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced the completion of enrolment of 506 patients in a global, randomized, double-blind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706 (PROSEEK).

"This is a significant milestone for SPARC & Vodobatinib. I would like to express my gratitude to all the patients, caregivers and the physicians associated with PROSEEK." said Anil Raghavan, CEO of SPARC.

About PROSEEK:
PROSEEK is global, randomized, double-blind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706/SCC-138.

The primary endpoint is the change from baseline to week 40 in the score of the MDS-UPDRS Part III (Movement Disorder Society – Unified Parkinson's Disease Rating Scale).

The key secondary endpoints include:

- Change from baseline to Week 40 in the sum of the MDS-UPDRS Parts II and III total scores
- Time from baseline to initiation of symptomatic medication
- Change in health-related quality of life as measured by the European quality of life questionnaire
- Change in Clinician global impression of severity

About Vodobatinib (SCC-138/K0706):
Vodobatinib is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor. Vodobatinib is being evaluated under multiple clinical trials in patients with Parkinson's disease, Dementia with Lewy Body and Chronic Myelogenous Leukemia.

About SPARC (CIN: L73100GJ2006PLC047837):
Sun Pharma Advanced Research Company Ltd. ('SPARC') is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the Company can be found at www.sparc.life.

Disclaimer:

Statements in this document describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

Media Contact:

Jaydeep Issrani
Tel +91 22 66455645, Extn: 5787
Tel Direct +91 22 6645 5787
Mobile +91-9820216916
E mail jaydeep.issrani@sparcmail.com